Document is current
Any future updates will be listed below
-
Authors
Mandal, Kamal
Wicaksono, Gianina
Yu, Clinton
Adams, Jarrett J.
Hoopmann, Michael R.
Temple, William C.
Izgutdina, Adila http://orcid.org/0000-0002-3296-3261
Escobar, Bonell Patiño http://orcid.org/0000-0003-2622-4822
Gorelik, Maryna
Ihling, Christian H. http://orcid.org/0000-0003-2419-4391
Nix, Matthew A. http://orcid.org/0000-0001-7741-5368
Naik, Akul
Xie, William H.
Hübner, Juwita
Rollins, Lisa A.
Reid, Sandy M.
Ramos, Emilio
Kasap, Corynn
Steri, Veronica
Serrano, Juan Antonio Camara
Salangsang, Fernando
Phojanakong, Paul
McMillan, Melanie
Gavallos, Victor
Leavitt, Andrew D.
Logan, Aaron C.
Rooney, Cliona M.
Eyquem, Justin http://orcid.org/0000-0001-8262-1190
Sinz, Andrea http://orcid.org/0000-0003-1521-4899
Huang, Benjamin J. http://orcid.org/0000-0001-6996-0833
Stieglitz, Elliot http://orcid.org/0000-0001-7032-4623
Smith, Catherine C.
Moritz, Robert L. http://orcid.org/0000-0002-3216-9447
Sidhu, Sachdev S. http://orcid.org/0000-0001-7755-5918
Huang, Lan http://orcid.org/0000-0002-3140-4687
Wiita, Arun P. http://orcid.org/0000-0002-7465-6964
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA263229, P30 CA082103, P30CA082103)
Michelson Prize and Grants (Michelson Prize)
American Society of Hematology (NA)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM087221, R01GM074830, R35GM145249, R01GM130144)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (S10OD026936)
National Science Foundation (1920268)
Gouvernement du Canada | Canadian Institutes of Health Research (MOPS-136944)
Bristol-Myers Squibb (NA)
- License Information
-
More Information
Article History
Received: 19 August 2022
Accepted: 12 September 2023
First Online: 30 October 2023
Competing interests
: K.M., J.J.A., S.S.S. and A.P.W. have filed a patent related to the antibody sequences described herein. A.P.W. has received research funding from Genentech. C.S. has received research funding from Revolution Medicines, Abbvie and Erasca and has served on advisory boards for Genentech, Abbvie and Astellas. C.M.R. has equity in Allovir and Marker Therapeutics, has received research support from Tessa Therapeutics and is on the Scientific Advisory Board of Tessa Therapeutics and Marker. The spouse of C.M.R. has served on advisory boards for Walking Fish Therapeutics, CellGenix, Marker Therapeutics, Tessa Therapeutics, Abintus, Allogene, Bellicum Pharmaceuticals, Bluebird Bio, Athenex, Memgen, Turnstone Biologics, Coya Therapeutics, TScan Therapeutics, Onkimmune, Poseida Therapeutics and Allovir. The other authors declare no competing interests.
